Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and maintains $155 price target.
Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $155 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.